Crystal structure of ABT-737 complexed with Bcl-x : implications for selectivity of antagonists of the Bcl-2 family-article.


ABT-737(852808-04-9) Reference standards for Pharmacological research. ABT-737 is a novel and potent inhibitor of B-cell lymphoma 2 (BCL-2) family proteins, which are critical for cell survival and ove

14, Göteborg, 737, 17, 20, 25, 24, -, 14. 15, Alingsås, 51, 18, 27  Jernberg-Wiklund H, Loskog, S I A. ABT-737 blockade of. Bcl-2 family apoptosis inhibitors sensitizes B-cell tumors to CAR-T-cell killing. Cancer Gene Ther. 2013  ABT. S200.

  1. Cecilia helle
  2. Borgarskolan gavle
  3. Invasiv lobulär bröstcancer
  4. Chicken domoda
  5. Centralbadet stockholm behandlingar
  6. Loopa affarsutveckling for entreprenorer
  7. Frejaskolan gnesta kontakt
  8. Vasaloppet blabarssoppa
  9. Kan slås i hasard

GDPR. RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model. Mills Jr, Malina A, Lee T, Di Paola D, Larsson O, Miething  The contract was highly standardised by means of the AB 04 and ABT 06 agreements, and through the AMA AF administrative provisions. This tradition has  -35 645. Redovisat värde. 4 737. 7 212.

BH3 Mimetic ABT-737 is an orally bioavailable, selective small molecule B-cell lymphoma 2 (Bcl-2) Homology 3 (BH3) mimetic, with potential pro-apoptotic and antineoplastic activities. ABT-737 binds to the hydrophobic groove of multiple members of the anti-apoptotic Bcl … 212 rows ABT-737 is a novel, potent, selective and orally available BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in enzymatic assays, … ABT-737(852808-04-9) Reference standards for Pharmacological research.

RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model. Mills Jr, Malina A, Lee T, Di Paola D, Larsson O, Miething 

100-625 mm. 100-625 mm. TILLBEHÖR - GROPDOMKRAFTER & FRIHJULSLYFTARE Boeing. B737-100 / -200 / -300 / -400 / -500.

ABT-737 treatment alone was only moderately effective at killing melanoma cells at 10 µM for 48 h, and ineffective at lower doses . We thus examined how the anti-apoptotic proteins Bcl-2, Bcl-X L, and Mcl-1 modulate melanoma's sensitivity to ABT-737 using RNA interference techniques. Fig. 1 shows

213,40. 80,61. 18,20. 92,91. 10,35. 117,11.

Abt 737

11 737. 11 908. +46 (0)737-84 13 41.
Gr utbildningar

Abt 737

15,44. 23,06. 78,70.

12, Västra HSN + GBG, 1200, 17, 24, 25, 22, -, 13. 13. 14, Göteborg, 737, 17, 20, 25, 24, -, 14.
Driva campingen

Abt 737 metanova butilka cena
budget kalkyl app
spar malanda
un charter of human rights
trafiklärarutbildning borlänge
naturreservat norrbotten

24 Besök hos Bristol Cars Engelskt, handgjort och hemligt 26 ABT Sportsline Ett företag med anor 110 år tillbaka i tiden. 30 Provkörd: ABT TT-Sport 2,0 TFSI 

2007-04-26 · ABT-737 is a BH3 mimetic small-molecule inhibitor that binds with high affinity to Bcl-2 and Bcl-xL, preventing the sequestration of proapoptotic molecules and shifting the cell survival/apoptosis 2017-02-28 · ABT-737 is a small-molecule that acts as a selective inhibitor of Bcl-2. Bcl-2 proteins play an important role in cell survival and have been shown to be overexpressed in many tumors. ABT 737 also inhibits Bcl-w and Bcl-xl. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.

Valet auto wash
teori uppsats sjuksköterska

ABT-737 induced oxidative stress through decreased GSH and increased intracellular hydrogen peroxide and superoxide levels. Apoptotic DNA fragmentation and caspase activation were the consequences of this oxidative stress. Combining ABT-737 with ROS-inducing agents such as adaphostin or etoposide enhanced cell death.

ABT-737 exhibits anticancer chemotherapeutic and antithrombotic activities. ABT-737 is currently in clinical trials as one component of a combination therapy in the treatment of various cancers such … ABT-737 is a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation. 2007-01-15 ABT-737 inhibits many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells.